Increase in H5N1 vaccine antibodies confers cross-neutralization of highly pathogenic avian influenza H5N1
Open Access
- 1 July 2025
- journal article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 5517
Abstract
H5N1, a highly pathogenic avian influenza virus, presents pandemic risks due to its ability to adapt and spread among mammalian species. Vaccination may control its spread, but the effectiveness of existing H5N1 vaccines against circulating strains, especially clade 2.3.4.4b, remains uncertain. In this study, we assess neutralizing antibody responses to global circulating H5N1 strains, using sera from individuals vaccinated with an inactivated H5N1 vaccine (NCT00535665). Neutralization is measured against 17 pseudoviruses, representing circulating and vaccine H5 strains. Our results indicate that broad protective effects are observed only when high antibody titers are achieved by vaccination. Correlation analysis estimates that a pseudovirus-based neutralization titer of at least 1:980 is required to achieve a cross-protection rate above 60%. The findings suggest that the current H5N1 vaccine can elicit cross-neutralization of circulating H5N1 strains, if high antibody titers are achieved. Until updated H5N1 vaccines are developed, this vaccine may serve as a bridging measure.Keywords
All Related Versions
This publication has 24 references indexed in Scilit:
- Isolation of clade 2.3.4.4b A(H5N8), a highly pathogenic avian influenza virus, from a worker during an outbreak on a poultry farm, Russia, December 2020Eurosurveillance, 2021
- Emergence and spread of novel H5N8, H5N5 and H5N1 clade 2.3.4.4 highly pathogenic avian influenza in 2020Emerging Microbes & Infections, 2021
- Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assayNature Protocols, 2020
- The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and AntigenicityCell, 2020
- The Ecology and Evolution of Influenza VirusesCold Spring Harbor Perspectives in Medicine, 2019
- Development of in vitro and in vivo neutralization assays based on the pseudotyped H7N9 virusScientific Reports, 2018
- Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus systemScientific Reports, 2017
- Immunogenicity, Safety, and Cross‐Reactivity of an Inactivated, Adjuvanted, Prototype Pandemic Influenza (H5N1) Vaccine: A Phase II, Double‐Blind, Randomized TrialClinical Infectious Diseases, 2009
- Human Immunodeficiency Virus Type 1envClones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing AntibodiesJournal of Virology, 2005
- DETERMINANTS OF IMMUNITY TO INFLUENZA INFECTION IN MANBritish Medical Bulletin, 1979